glp-1 als Doctors warn drugs may speed decline Science's 2023 Breakthrough: GLP-1R Agonists

Available from: Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA (2009) Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions

Is It Possible To Stop Using GLP-1 Medications

TyG: triglyceride-glucose

Abstract Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity

Diabetes Care 37 , e11e12 (2014)

Often considered a silent disease, MASH frequently presents no noticeable symptoms until substantial liver damage has already occurred, making early detection through regular screenings vital to prevent further progression and complications